Start here if you're new
what it is
Pelthos sells one approved skin gel and is adding a second product plus pain assets.
how it gets paid
Last year Pelthos Therapeutics made n/a in revenue. ZELSUVMI commercial sales was the main engine at $7.0M, or 100% of sales.
what just happened
Pelthos posted $294K in quarterly revenue and lost $14.96 a share.
At a glance
n/a balance sheet
-$14.30 fy2024 eps est
n/a operating margin
1.4 beta
~$79M market cap
What they do
Pelthos sells one approved skin gel and is adding a second product plus pain assets.
ZELSUVMI got FDA approval in 2024 and launched in July 2025. That gives you a real product, not a slide deck. Pelthos also bought Xeglyze for $1.8 million, so a second shot did not cost much. With 4 employees, the whole business runs on a very small machine.
How they make money
n/a
annual revenue
ZELSUVMI commercial sales
$7.0M
Xeglyze
$0
NITRICIL platform
$0
NaV1.7 pain assets
$0
The products that matter
commercial dermatology drug
ZELSUVMI
$7.4M quarterly sales · 100% of revenue
It generated $7.4M in its first full reported quarter of sales, which means the entire revenue line currently rises or falls with one product launch.
100% of revenue
Key numbers
$79M
market cap
You are paying $79M for a company with one commercial product and $294K of quarterly revenue.
$294K
quarterly rev
That is the latest quarter's sales. It is tiny next to a $79M market cap.
-$14.96
quarterly eps
Each share lost $14.96 last quarter, which is a rough ratio against a $20.58 stock.
$3M
long-term debt
Debt is only 3% of capital, so leverage is not the drama yet.
Financial health
n/a
strength
- balance sheet grade n/a
- price stability 5 / 100
- long-term debt $3M (3% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for PTHS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Pelthos posted $294K in quarterly revenue and lost $14.96 a share.
ZELSUVMI launched in July 2025, so the revenue base is still early. The quarter shows a real product, but the sales number is tiny.
$294K
revenue
-$14.96
eps
n/a
n/a
revenue
Revenue was $294K. That matters because it shows the launch is real, but still very small.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is ZELSUVMI launch failure. This is not a diversified biotech page. It is one commercial asset carrying the full revenue line.
med
single-product concentration
All reported revenue on this page comes from ZELSUVMI. If prescriptions flatten or reimbursement disappoints, there is no second engine to hide behind.
Impact: 100% of the current $7.4M revenue base is tied to one product.
med
launch economics do not work yet
The company lost $16.2M in the same quarter it produced $7.4M in sales. Revenue growth can look good on paper and still fail to cover commercialization costs.
Impact: until the loss line starts narrowing, each quarter is still a funding question as much as a sales update.
med
debt and timeline pressure
This page references a recent $50M senior secured term loan while profitability is targeted for 2028. Debt can buy time. It also makes time more expensive.
Impact: if breakeven slips again, the balance-sheet story gets harder, not easier.
A stall in ZELSUVMI uptake would pressure 100% of current revenue while the company still carries a $50M loan and aims for profitability only by 2028.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number that mattered
whether revenue grows faster than the loss line
$7.4M in sales is a start. The real question is whether the next quarter shows operating leverage instead of just more spending.
calendar
March 19, 2026 earnings
This is the next clean read on ZELSUVMI demand, launch efficiency, and management's path to 2028 profitability.
trend
breakeven timing
The story is manageable if 2028 stays credible. Another pushout would tell you the launch economics are weaker than hoped.
risk
how the $50M loan changes the equity story
Fresh financing helps survival. It also means shareholders need the commercial ramp to work before the capital structure gets heavier.
Analyst rankings
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for PTHS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$21
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive